Galderma Group AGXSWX:GALD -1.01%15 Receivables Turnover is 3.14 as of Dec. 2025. GuruFocus rates XSWX:GALD with a GF Score™ of 15/100. The stock has 4 warning signs investors should review. Among 947 Drug Manufacturers companies, Galderma Group AG ranks better than 63.36% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Galderma Group AG's Revenue for the
six
months ended in Dec. 2025 was CHF2,211 Mil. Galderma Group AG's average Accounts Receivable for the
six
months ended in Dec. 2025 was CHF704 Mil.
Hence, Galderma Group AG's Receivables Turnover for the
six
months ended in Dec. 2025 was 3.14.
Galderma Group AG (XSWX:GALD) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Galderma Group AG Receivables Turnover Related Terms
Galderma Group AG Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Galderma Group AG's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:GALD vs ZTS, UTHR, VTRS: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Galderma Group AG's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Galderma Group AG Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Galderma Group AG's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Galderma Group AG's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Galderma Group AG (XSWX:GALD) has a Receivables Turnover of 3.14 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Galderma Group AG and its competitors. According to the industry distribution chart, Galderma Group AG ranks #347 out of 947 companies in the Drug Manufacturers industry, placing it in the top 36.6%.
Is Galderma Group AG's Receivables Turnover too high?
Galderma Group AG's current Receivables Turnover is 3.14. The Drug Manufacturers industry median Receivables Turnover is 5.07. Galderma Group AG's value of 3.14 is 38.1% below this industry median. Based on the distribution chart, Galderma Group AG ranks #347 out of 947 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Galderma Group AG has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Galderma Group AG's Receivables Turnover compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Galderma Group AG ranks #347 out of 947 companies for Receivables Turnover. This puts Galderma Group AG in the upper half of its industry. The industry median Receivables Turnover is 5.07. Galderma Group AG's value of 3.14 is 38.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Galderma Group AG's current Receivables Turnover of 3.14 is 38.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Galderma Group AG and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Galderma Group AG's current Receivables Turnover is 3.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galderma Group AG stock overvalued right now?
Galderma Group AG (XSWX:GALD) has a current Receivables Turnover of 3.14. The current Receivables Turnover is 3.14 and 38.1% below the Drug Manufacturers industry median of 5.07. Galderma Group AG's overall GF Score™ is 15/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Galderma Group AG (XSWX:GALD), the current Receivables Turnover is 3.14 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
15GF Score
Get the complete analysis for XSWX:GALD
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:GALD has been successfully added to your 